<DOC>
	<DOCNO>NCT00643123</DOCNO>
	<brief_summary>The purpose study investigate efficacy allopurinol augmentation agent treatment resistant mania mixed mania .</brief_summary>
	<brief_title>Allopurinol Add-on Treatment Refractory Mania</brief_title>
	<detailed_description>Bipolar disorder severe mental disorder episode mania depression . Current medication mania significant side effect , high cost need blood monitoring . The purpose research study study effectiveness allopurinol , combination lithium valproic acid carbamazepine , treatment-resistant bipolar mania mixed mania . This research study design test safety and/or effectiveness allopurinol approve U.S. Food Drug Administration ( FDA ) recurrent calcium renal calculus , gout , hyperuricemia ( cancer tumor lysis syndrome ) , approve use treatment-resistant bipolar mania mixed mania . Participants double-blind study randomly assign one two study group . The first group receive study medication allopurinol second group receive placebo . These take conjunction current medication dos . The study last 7 week ( initial screening , baseline visit 4 follow-up visit week 1,2,4 , 6 ) . The initial screening visit use determine whether subject able participate study . The following conducted screen visit : Review medical psychiatric history along standard psychiatric assessment exam ; Physical examination , include review prior current medication adverse drug effect ; An electrocardiogram ( ECG ) - painless test do attach strap pad limbs chest record electrical pattern heart , do record heart rhythm ; About 5 tablespoon blood drawn ass basic laboratory value show healthy enough participate study ; Blood level lithium , valproic acid , and/or carbamazepine measure ; A urine sample collect test presence illegal drug pregnancy test ( female child-bearing potential ) ; Collection demographic data ( e.g. , age , gender , marital status , social vocational status ) information include health belief , knowledge illness . At baseline visit participant give questionnaire related mood , quality life , disability , medication , side effect . The participant 's vitals ( temperature , weight , heart rate , blood pressure ) measure . The participant randomize treatment ( 300 mg allopurinol/day ) placebo . After week one Week 1 visit , tolerate dosage allopurinol get increase dosage . The participant also complete set questionnaire . Vitals take . The remain follow-up visit similar visit one except increase dosage ; Week 2 include blood draw measure level lithium , valproic acid , and/or carbamazepine participant 's blood , final visit Week 6 addition include blood draw , exit physical exam , urine sample collect .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Subjects must age 18 70 . Subjects must meet DSMIV criterion bipolar disorder , recent episode manic mixed , time screen confirm Mini International Neuropsychiatric Interview ( MINI ) . Subjects must take least one medication mania ( lithium , valproic acid , carbamazepine ) therapeutic dose least 4 week . Subjects must nonresponse partial response medication evidence Young Mania Rating Scale ( YMRS ) score great equal 14 screen baseline . Female subject must either postmenopausal least 1 year , surgically sterile , abstinent practice effective method birth control sexually active . Female subject must also negative urine pregnancy test screening , baseline time point throughout study . Subjects must able willing comply selfadministration medication consistent help/support available . Subjects must sign informed consent document indicate understand purpose procedure require study willing participate study . Subjects must able willing meet perform study requirement ( e.g . answer selfadministered questionnaire ) . Subjects must willing allow study staff contact subject 's regular psychiatrist subject study . Subjects unable provide inform consent . Subjects serious , unstable medical illness ( cardiovascular , respiratory , neurologic , hematologic , renal , hepatic , endocrine , immunologic , systemic illness ) , history cerebrovascular disease , uncontrolled diabetes mellitus AIDS . Subjects chronic illness must stable otherwise physically healthy basis physical examination , medical history , electrocardiogram result blood biochemistry , hematology test urinalysis . Subjects history substance abuse dependence ( exclude nicotine caffeine ) accord DSMIV criterion within last 4 week . Subjects take azathioprine , mercaptopurine , apalcillin , and/or amoxicillin . Subjects take dopamine agonist and/or antipsychotic . Subjects intoxicate alcohol illicit drug within 3 day prior baseline . Subjects history severe preexist gastrointestinal narrowing inability swallow oral study medication whole aid water . Female subject pregnant nursing . Subjects previously participate study . Subjects anticipated life expectancy 6 month less . Subjects receive experimental drug use experimental medical device within 1 month screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Mania</keyword>
	<keyword>Mixed mania</keyword>
	<keyword>Allopurinol</keyword>
	<keyword>Treatment-Resistant mania</keyword>
</DOC>